To characterize the risk factors, clinical course, and treatment of patients with progressive multifocal leukoencephalopathy (PML) diagnosed and followed over a 25-year epoch at 2 academic hospitals.
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the CNS caused by reactivation of JC virus leading to oligodendrocyte destruction. Similar to other human polyoma viruses, JC virus is an opportunistic pathogen, with PML manifesting primarily in patients with innate immunodeficiency or taking immunomodulatory medications. The pathology of PML was first reported in 1958 in a patient with chronic lymphocytic lymphoma. 1 By 1982, the syndrome had been characterized in HIV-infected patients. 2 In 2005, PML was first reported in patients treated with natalizumab, a monoclonal antibody approved by the Food and Drug Administration to treat relapsing-remitting MS (RRMS). 3, 4 PML has been reported in association with rheumatologic diseases, lymphoreticular malignancies, and post-organ transplantation immunosuppression, and less frequently, in cases without recognized immunosuppression. As new immunosuppressive therapies are introduced and used increasingly broadly across disease states, PML has been described in association with rituximab, cyclophosphamide, methotrexate, mycophenolate mofetil, dimethyl fumarate, fingolimod, and cyclosporine. [5] [6] [7] Treatment options for PML are limited. Withdrawal of immunosuppressive medications and, in the case of HIVinfected individuals, provision of antiretroviral therapy offer the only clear survival benefit. 8 Previous studies have explored the efficacy of 5-hydroxytryptamine antagonists including mirtazapine and risperidone, nucleoside analogs including cidofovir and cytosine arabinoside, and biological therapies including interferon alpha, without proven efficacy. [9] [10] [11] [12] More recently, favorable outcomes have been reported in patients treated with immune checkpoint inhibitor therapy [13] [14] [15] and infusion of virus-specific T cells. 16 Although large cohorts of patients with PML in the setting of natalizumab have been described, 17, 18 most of the literature on diverse etiologies of PML in recent decades has been limited to small case series and individual reports, which are subject to publication bias based on either unexpectedly favorable or unfavorable outcomes. 19, 20 With the new promise of effective therapy for this devastating disease, understanding the diverse presentations of PML is increasingly important because early manifestations may be difficult to recognize but are most amenable to treatment. Here, we report the risk factors and outcomes in a cohort of patients diagnosed with PML and followed at 2 tertiary care hospitals in the United States over a 25-year period.
Methods

Ethics
The study protocol was approved by the Partners Healthcare Institutional Review Board of Massachusetts General Hospital.
Patient identification
Patients were identified by searching the Partners Health Care Research Patient Data Registry system using the International Classification of Diseases 9th and 10th edition diagnostic codes for PML (046.3, A81.2). All patients who were diagnosed with PML and presented to Massachusetts General Hospital or Brigham and Women's Hospital between January 1, 1994, and January 1, 2019, were included on initial review (figure 1). These dates were chosen based on the initiation of electronic medical records at the study's hospitals.
Diagnostic criteria
Patients with a definite diagnosis of PML were identified using diagnostic criteria previously published by the American Academy of Neurology (AAN). 21 For patients with available histopathology, this included the presence of demyelination, bizarre astrocytes, enlarged oligodendroglial nuclei, and either positive tissue PCR for JC virus, positive immunohistochemistry, or visualization of viral particles using electron microscopy. For patients without histopathology, this included the presence of compatible clinical features, compatible radiologic findings, and a positive CSF PCR for JC virus. Patients whose available medical records were limited to histopathology results without clinical data were excluded from analysis. All included patients were diagnosed and treated by a neurologist before the authors' electronic medical records review.
Data collection and variables
Data on the initial clinical presentation and follow-up, until a censoring date of June 1, 2019, were collected in a central database. Variables of interest included sex, date of birth, clinical outcome, date of PML-related symptom onset, date of PML diagnosis, HIV infection status, malignancy status, transplantation status, immunosuppressive medications, CSF profile, JC virus positivity in serum and CSF, JC virus copy number or index value, and PML treatment modalities pursued. Previously published clinical diagnostic criteria were used to identify patients who developed immune reconstitution inflammatory syndrome (IRIS). 22 For patients who were HIV infected, CD4 count and HIV viral load at the time of PML diagnosis were included. Presenting symptoms were reviewed and categorized. Glossary AAN = American Academy of Neurology; cART = combined antiretroviral therapy; IRIS = immune reconstitution inflammatory syndrome; mRS = modified Rankin Scale; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS.
The first brain MRI obtained for each patient after the onset of symptoms were reviewed by a study neurologist (P.A.) and coded with respect to multifocality, presence or absence of gadolinium enhancement, and the anatomic location of lesions. Histopathology reports obtained through brain biopsy or autopsy were reviewed and coded with respect to the presence or absence of demyelination, bizarre astrocytes, enlarged oligodendroglial nuclei, tissue PCR, immunohistochemistry, and visualization of viral particles using electron microscopy. All treatments administered for PML were recorded for each patient.
For patients for whom a date of death was not recorded, a search of the US Social Security Administration Death Master File and the Massachusetts Registry of Vital Records and Statistics was performed to determine the date of death. For patients who remained alive as of April 1, 2019, a modified Rankin Scale (mRS) score was calculated at the last clinical follow-up. Patients who had last been seen by a neurologist more than 1 year earlier had an mRS determined through a telephone assessment. Patients who were diagnosed with PML on June 1, 2009, or earlier were eligible to be 10-year survivors in this study.
Statistical analysis
All analyses were completed using Microsoft Excel TM and Python 2.7.14. Patient characteristics were summarized by expressing categorical variables as counts and proportions and continuous variables as medians. Major risk factors for PML were studied for prevalence in 5-year epochs, beginning with the study observation period's first observed time point on January 1, 1994, and counted as every 5 years afterward.
Patients with HIV infection were compared with all those without HIV infection using the 2-proportion z-test for differences in proportions, the unequal variance t-test for differences in means, and the Kruskal-Wallis test for differences in medians.
A Kaplan-Meier estimator was used to graph the survival of patients from the time of PML diagnosis to either death or the date of last known follow-up. The median survival was compared between HIV-infected and non-HIV-infected patients using a log-rank test. A p value of 0.05 or less was considered statistically significant.
Data availability
Data will be made available upon reasonable request by qualified investigators and subject to ethics board approvals.
Results
Patient characteristics
There were 91 patients (n = 53, 58% male) with confirmed PML with a median age at symptomatic onset of 53 years (range 24-80 years) (table 1). HIV-infected PML patients were younger at the time of symptomatic onset, with a median age of 42 years compared with 67 years in HIV-uninfected patients (p < 0.001). HIV-infected patients were more often male (71%, n = 32) compared with HIV-uninfected patients (46%, n = 21) (p = 0.014). The most common presenting symptoms observed were hemiparesis and gait and speech abnormalities.
The median time between symptomatic onset and diagnosis of PML was 40 days, with a minimum time of 5 days and a maximum time of 2 years, the latter in a patient with Figure 1 Flowchart describing the selection of this cohort idiopathic lymphopenia. Time to diagnosis was shorter in HIV-infected patients vs HIV-uninfected patients, but this was not statistically significant (32 vs 48 days, p = 0.199). Among patients with lymphoma, leukemia, or myelodysplasia, the median time to diagnosis was 48 days. Seventeen patients had a JC viral copy number tested in CSF at the time of PML diagnosis, with a median of 2,430 copies.
PML risk factors
The major predisposing factors for PML are reported in table 1, with risk factors categorized by 5-year epoch reported in table 2. HIV infection was the most common risk factor, identified in 49% of the 91 patients. Other frequent risk factors included lymphoma, leukemia, or myelodysplasia, identified in 31% of patients (n = 28), exposure to chemotherapeutic medications (30%, n = 27), and exposure to monoclonal antibody therapies (19%, n = 17). Several patients had exposure to multiple risk factors; for instance, 20 patients with lymphoma, leukemia, or myelodysplasia were Lymphoma, leukemia, or myelodysplasia 28 31
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Rheumatologic disease-modifying drug g 8 9 Among the 3 patients with solid organ transplants, 1 had undergone a double-lung transplant 4 years before the onset of PML symptoms, followed by a combined double-lung and kidney transplant 2 months before symptom onset for cystic fibrosis; 1 had undergone a single kidney transplant 19 years before symptom onset and was awaiting a liver transplant for hepatorenal syndrome secondary to alcoholic cirrhosis; and 1 had undergone an orthotopic heart transplant for nonischemic cardiomyopathy 2 years before the onset of symptoms.
Among the 3 patients with bone marrow and stem cell transplants, 1 had undergone a stem cell transplant 10 years before the onset of PML symptoms for chronic lymphocytic leukemia, followed by treatment with cyclophosphamide, vincristine, prednisone, and fludarabine for recurrent leukemia beginning 2 years before symptom onset complicated by pancytopenia; 1 had undergone a bone marrow transplant for non-Hodgkin lymphoma 2 years before symptom onset, followed by treatment with cyclophosphamide, rituximab, and radiation 1 year before symptom onset; and 1 had undergone autologous stem cell transplant 4 years before symptom onset and allogenic stem cell transplant for relapsed disease 2 years before symptom onset, followed by therapy with rituximab and brentuximab for graft vs host disease beginning 3 months before symptom onset.
Four patients with a diagnosis of RRMS were included in the cohort. One patient had been treated with dimethyl fumarate since diagnosis with RRMS 3 years before the onset of PML symptoms. Three patients were treated with natalizumab. One patient had been on natalizumab for 3 years before the onset of PML symptoms and had previously been treated with interferon beta-1a and glatiramer acetate; 1 patient had been on natalizumab for 8 years before symptom onset and had been previously treated with interferon beta-1b and glatiramer acetate; and 1 patient had been on natalizumab for 1 year before symptom onset and had previously been treated with interferon beta-1a and glatiramer acetate. All 4 patients with RRMS were alive as of the censoring date, with durations of follow-up between 4 and 7 years. Three presented with new neurologic symptoms, including dysarthria, dysmetria, gait instability, headache, and visual changes. One was asymptomatic and was evaluated for PML because of changes seen on a surveillance brain MRI.
Survival analysis
Vital status could not be ascertained in 1 patient, who was excluded from the analysis of final outcomes. Thirty percent of the cohort was alive at the time of censoring (27/90), with a median mRS of 2 points (slight disability) at last follow-up. Eight patients had an mRS of 0 points (no symptoms, 30%), 5 had an mRS of 1 point (no significant disability, 19%), 6 had an mRS of 2 points (slight disability, 22%), 1 had an mRS of 3 points (moderate disability, 4%), 4 had an mRS of 4 points (moderately severe disability, 15%), and 3 had an mRS of 5 points (severe disability, 11%). One patient was diagnosed on the day of death. Median survival following PML was longer in patients who were HIV-infected patients (1,992 days) compared with patients who were HIV uninfected (101 days, p = 0.024) (figure 2).
Forty patients survived more than 1 year after the onset of PML symptoms, of whom 24 were HIV infected (60%). Thirty-three of 45 HIV-infected patients (73%) and 24/46 HIV-uninfected patients (52%) were diagnosed before June 1, 2009, and eligible for 10-year survivor status. Thirteen of 59 eligible patients survived more than 10 years after PML symptom onset (22%). Ten-year survivors were all HIV infected, with either a new diagnosis of HIV at the time of PML diagnosis or nonadherence with previously prescribed combined antiretroviral therapy (cART) (table 3). Five 10year survivors were diagnosed with PML-IRIS following the PML diagnosis. Follow-up brain imaging in 10-year survivors predominantly revealed brain volume loss in areas that were previously involved by PML on initial imaging ( figure 3 ). In addition to 10-year survivors, 2 patients survived for more than 5 years after the onset of symptoms; 1 was HIV infected, and 1 had RRMS and exposure to natalizumab. No PML disease relapses were noted in any PML survivors.
PML-directed treatment
All HIV-infected patients were started on cART following PML diagnosis (n = 46). Thirty-seven percent (n = 34) of patients were treated with mirtazapine, and 15% (n = 14) were treated with mefloquine (table 4) . Other therapies used in the treatment of PML included adoptive T-cell therapy, checkpoint inhibitor therapy, cidofovir, cytosine arabinoside, interferon alpha-2A, interleukin-2 inhibitor, IV immunoglobulins, and plasmapheresis. All 10-year survivors of PML were initiated on cART, and 1 was treated with cytosine arabinoside. No other PML-directed therapies were used in the treatment of patients who survived 10 or more years after PML symptom onset.
Discussion
Epidemiologic studies of PML remain rare despite the widespread awareness of the condition. Our findings demonstrate that, as PML is seen less often in HIV-infected individuals, new and repurposed immunosuppressive medications are increasingly recognized as predisposing factors for PML. Much attention has been focused in recent years on specific PML risk factors, including HIV infection and the use of natalizumab therapy in patients with RRMS. Although our study is not population based and does not report on incidence, we provide granular clinical data from 2 large academic tertiary care hospitals to elucidate the etiologies and outcomes for PML patients. We show here that despite previous interest in single medications or disease processes, PML occurs due to a broad range of risk factors that are often multiple and overlapping. This includes patients who both have underlying risk such as malignancy or rheumatologic disease and are exposed to 1 or more immunosuppressive medications.
Previous large cohort studies have focused on HIV infection as a predisposing risk factor for PML and have shown a decrease in the incidence of PML in HIV-infected patients with the advent of cART. In the pre-cART era, 1 study of 79 HIVinfected patients diagnosed between 1979 and 1983 at a single center found that 3.8% had PML. 23 A Danish cohort of 47 HIVinfected patients with PML identified during the pre-cART (1995) (1996) , early cART (1997) (1998) (1999) , and late cART (2000-2006) periods found that although the incidence of PML in HIV-infected patients had decreased, survival remained poor, with a median duration of 146 days. 24 A prospective French study of 92,477 HIV-infected patients followed between 1997 and 2011 found that 555 developed PML, with a decrease in incidence of 57% over the 15-year study period. 25 The Swiss HIV cohort followed 186 HIV-infected patients with PML and found a decrease in PML incidence and mortality associated with cART independent of baseline CD4 T-cell count. 26 Here, we find that the median survival following PML in HIV-infected patients is longer than in HIV-uninfected patients (1,992 vs 101 days, p = 0.024). The most common presenting symptoms in our cohort, hemiparesis and gait and speech abnormalities, reflect those described in the largest HIV-PML cohort described in the literature. 2 Limited literature exists on longer-term survivors of PML. A 2010 study described the clinical outcome of 24 patients with PML whose survival exceeded 5 years, demonstrating that the majority of survivors improved or were stable in their deficits after 5 years from onset of symptoms. 27 As in our study, the majority of long-term survivors of PML were found to be HIV infected. Here, we report on the outcomes of thirteen 10-year survivors of PML out of 59 patients who were followed for 10 or more years after the onset of symptoms, including 1 patient followed at our center for >18 years. We have performed nearly a complete case analysis, with only 1 patient lost to follow-up, allowing for robust estimates of survival and functional outcome among survivors. All the 10-year PML survivors in our study were HIV infected, with 1 patient with RRMS who survived for more than 5 years following natalizumab-induced PML. As a more positive finding, the majority of PML survivors in our cohort had either no or slight disability at the time of follow-up, suggesting that those who survive can anticipate functional independence in most cases. These findings may help to inform prognostication in future cases of PML. Although multiple therapeutic options have been offered in the treatment of PML, all the 10-year survivors in our cohort were treated with cART, and just 1 received another PML-directed therapy.
We also identify a diagnostic delay, with a median time to diagnosis of 40 days. This finding replicates earlier studies demonstrating frequent misdiagnosis of PML, including a retrospective Swedish national study from 1988 to 2013. 28 A separate Boston-based retrospective study at a different institution covering the years 1993-2015 reported a median time from initial PML symptom onset to PML diagnosis of 74 days. 29 In nearly two-thirds of patients, a different diagnosis was first considered. Our cohort included a patient with unexplained lymphopenia who was diagnosed with PML 2 years after the initial onset of symptoms. In an era of available PMLdirected therapy, this delay may affect clinical outcomes.
In part, this delay may be fueled by stringent criteria for a diagnosis of PML. A Dutch-Belgian cohort of 28 patients with PML found that 18 patients met the AAN criteria 21 for high diagnostic certainty for PML at initial evaluation, which increased to 20 patients on follow-up evaluation. 30 The remainder of the cohort was classified as either "possible PML" or "not PML" despite a very high suspicion for PML based on MRI characteristics. A second study of 128 patients with PML in the setting of natalizumab exposure found that JC virus detection in CSF had a poor sensitivity for the diagnosis of early PML. 31 Earlier proposed criteria were formulated for patients with exposures to specific risk factors. 32 These failed to account for exposures to a diverse profile of overlapping risk factors.
Our study is limited by its retrospective nature. It is also subject to referral bias. In particular, the hospitals included in this analysis are both tertiary care centers and may be enriched for an oncologic population, as well as for less common underlying risk factors and exposures. Our study did not include city-or state-wide data and did not capture data from the public hospitals in the region. Both hospitals primarily care for adult patients, and our data collection expectedly captured no pediatric cases. Although PML is rarely seen in children, pediatric cases are described in the literature. 33 Our cases were subject to strict selection criteria: the requirement for CSF JC virus PCR positivity or histopathology to make a definitive diagnosis of PML. These criteria may have selected for more severe cases that proceeded to lumbar puncture or brain biopsy. Although this provides a high level of confidence in the accuracy of the diagnosis in included cases, our use of stringent criteria almost certainly underestimated the number of PML cases by eliminating cases that were based on neuroimaging findings alone. Finally, because we used a variety of sources to ascertain vital status at the censoring date, we are unable to comment on cause of death in our patient population. Patients who died with PML may not have died because of PML in all cases, particularly given the independent contribution of underlying risk factors.
Unlike other recent studies that result from drug safety programs or disease-specific entities, our work includes the range of risk profiles for PML in a large, academic, US setting. This adds to the limited literature comprising PML cohorts with large sample sizes. Survival following PML remains short for most patients at less than 2 months. However, long-term survivorship is possible in those with HIV infection and initiation of cART. Although we cannot conclude that any specific cART regimen was definitely effective for long-term survival, we present the regimens that have been successfully used at our center for patients with HIV-PML who survived 10 or more years after the onset of PML symptoms. We provide observational, retrospective data on a range of other attempted therapies in our patients for other researchers to include and synthesize across centers in future studies. Finally, our study offers a historical comparison for treatment cohorts as promising PML therapies enter into clinical trials. [13] [14] [15] [16] Study funding No dedicated study funding.
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